Press Releases May 12, 2026 10:27 AM

NEXGEL To Report First Quarter 2026 Financial Results on May 15th

NEXGEL announces Q1 2026 financial results release and conference call scheduled for May 15.

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
NXGL

NEXGEL, a US-based healthcare and consumer products company specialized in hydrogel technologies, will report its first quarter 2026 financial results on May 15, 2026. The company will hold a conference call at 12:00 P.M. ET the same day to discuss the results. NEXGEL has a strong presence in healthcare, beauty, and OTC products and maintains strategic contract manufacturing partnerships.

NEXGEL To Report First Quarter 2026 Financial Results on May 15th
NXGL
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • NEXGEL will release Q1 2026 financial results on May 15, 2026, after market close.
  • The company will host a conference call for investors and analysts on the same day at 12:00 P.M. ET.
  • NEXGEL focuses on healthcare, beauty, and OTC products with notable hydrogel brands and contract manufacturing partnerships.

Management Will Host a Conference Call at 12:00 P.M. ET on the Same Day

LANGHORNE, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the first quarter 2026 ended March 31, 2026, on Friday, May 15, 2026. Following the release of its financial results, the Company will host a conference call at 12:00 P.M. ET on the same day.

First Quarter 2026 Financial Results Conference Call:
Date: May 15, 2026
Time: 12:00 P.M. ET
Live Call: 1-800-267-6316 (U.S. Toll Free) or 1-203-518-9783 (International)
Webcast: Events and Presentations

For interested individuals unable to join the conference call, a replay will be available through May 29, 2026, by dialing 1-844-512-2921 (U.S. Toll Free) or 1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 11161819. An archived version of the webcast will also be available for 90 days.

About NEXGEL, Inc.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.

Investor Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Nexgel@KCSA.com


Risks

  • The article provides no indications of performance or guidance, so financial results could vary and impact stock price.
  • Market reaction depends on actual reported earnings, revenue, and outlook, which are yet unknown at this time.
  • Broader economic or healthcare market conditions may affect NEXGEL's future performance and supply chain stability.

More from Press Releases

Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress Jun 14, 2026 Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 Jun 14, 2026 Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026 Jun 14, 2026 Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control Jun 14, 2026 Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026